Moderna, Inc. $MRNA Stock Acquired by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC raised its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 14.0% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 30,053 shares of the company’s stock after buying an additional 3,698 shares during the period. Nisa Investment Advisors LLC’s holdings in Moderna were worth $5,787,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Robeco Institutional Asset Management B.V. purchased a new position in shares of Moderna during the third quarter valued at approximately $1,452,000. West Branch Capital LLC bought a new position in shares of Moderna during the third quarter valued at approximately $193,000. Kercheville Advisors LLC purchased a new stake in Moderna in the third quarter worth $260,000. Abel Hall LLC purchased a new stake in Moderna in the third quarter worth $399,000. Finally, OceanIQ Capital LLC purchased a new stake in Moderna in the third quarter worth $385,000. Institutional investors own 75.33% of the company’s stock.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna and Merck reported positive Phase 3 INTerpath-001 results for the personalized mRNA cancer vaccine, intismeran autogene, used with Keytruda. The treatment reduced the risk of melanoma recurrence or death by 42%, while also improving distant metastasis-free survival. Oncologists described the findings as a major advance in melanoma care. Nature article
• Positive Sentiment: The results strengthen the case for Moderna’s oncology pipeline and could support a major future revenue stream beyond COVID-19 vaccines, particularly if additional trials demonstrate benefits in other cancers. Moderna has also advanced its mRNA bird-flu vaccine into a late-stage trial, adding another potential pipeline catalyst. Bird flu vaccine trial article
• Neutral Sentiment: Moderna’s recent addition to the Nasdaq-100 and analyst support provide structural and sentiment benefits, but these factors have less immediate influence than the cancer-vaccine readout. The stock had already posted an exceptionally strong rally, leaving the valuation highly sensitive to new clinical information. Nasdaq-100 inclusion article
• Negative Sentiment: Partial trial data appeared on social media ahead of Moderna and Merck’s planned ESMO presentation, triggering extreme volatility and a sharp selloff. The premature release disrupted the expected news event and encouraged a “sell-the-news” reaction. CNBC data leak article
• Negative Sentiment: Although clinically meaningful, the 42% reduction fell short of the market’s very high expectations after Moderna’s dramatic run-up. Investors also questioned whether the results will translate beyond melanoma, how quickly the product could reach the market, and its eventual commercial opportunity. The breach of near-term technical support and heightened trading swings add further pressure. Zacks analysis

Wall Street Analyst Weigh In

MRNA has been the topic of several recent analyst reports. UBS Group reiterated a “neutral” rating on shares of Moderna in a report on Tuesday, September 22nd. Brookline Capital Markets restated a “buy” rating on shares of Moderna in a report on Wednesday, August 19th. Loop Capital set a $135.00 target price on shares of Moderna in a research report on Wednesday, August 19th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Moderna in a research note on Friday, September 25th. Finally, Rothschild & Co Redburn cut shares of Moderna from a “neutral” rating to a “sell” rating and boosted their price target for the company from $40.00 to $81.00 in a research report on Thursday, September 3rd. Seven analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and four have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $103.95.

Insiders Place Their Bets

In other Moderna news, CFO Jamey Mock sold 34,836 shares of the firm’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the completion of the transaction, the chief financial officer owned 59,375 shares of the company’s stock, valued at approximately $7,985,343.75. This trade represents a 36.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Stephen Hoge sold 39,145 shares of Moderna stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $220.72, for a total transaction of $8,640,084.40. Following the transaction, the president owned 1,636,565 shares of the company’s stock, valued at $361,222,626.80. The trade was a 2.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 197,251 shares of company stock worth $33,875,904. 10.80% of the stock is currently owned by company insiders.

Moderna Stock Performance

Shares of MRNA stock opened at $200.10 on Friday. The company’s fifty day moving average price is $172.79 and its 200-day moving average price is $96.96. The stock has a market cap of $79.89 billion, a PE ratio of -25.04 and a beta of 1.09. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $254.48.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The company had revenue of $145.00 million during the quarter, compared to analyst estimates of $102.93 million. During the same period last year, the business earned ($2.13) EPS. Moderna’s quarterly revenue was up 2.1% compared to the same quarter last year. On average, equities analysts expect that Moderna, Inc. will post -6.11 EPS for the current fiscal year.

About Moderna

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.